Enteric Softgel Capsules MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy End UserBy Distribution ChannelBy Manufacturing Technology
Full title & scope — all 5 axes with their segments
Enteric Softgel Capsules Market Size, Share & Industry Analysis, By Type (Gelatin Type, Vegetable Type), By Application (Antacid and Antiflatulent Preparations, Antibiotic and Antibacterial Drugs, Vitamins and Dietary Supplements, Cold, Cough and Analgesic Preparations, Others), By End User (Pharmaceutical Manufacturers, Nutraceutical and Dietary Supplement Companies, Contract Manufacturing Organizations), By Distribution Channel (Direct/Institutional Sales, Retail Pharmacies and Drug Stores, Online Retail), By Manufacturing Technology (Rotary Die Encapsulation, Seamless Encapsulation), and Regional Forecast, 2026-2034
Segment definitions and share of revenue by product, animal, end user and region.
- 01By TypeGelatin Type · Vegetable Type
- 02By ApplicationAntacid and Antiflatulent Preparations · Antibiotic and Antibacterial Drugs · Vitamins and Dietary Supplements
- 03By End UserPharmaceutical Manufacturers · Nutraceutical and Dietary Supplement Companies · Contract Manufacturing Organizations
- 04By Distribution ChannelDirect/Institutional Sales · Retail Pharmacies and Drug Stores · Online Retail
- 05By Manufacturing TechnologyRotary Die Encapsulation · Seamless Encapsulation
- 06By Region
Market Analysis & Outlook
Enteric softgel capsules are a soft-shell capsule format coated or formulated so that the fill dissolves only after passing through the stomach, protecting acid-sensitive active ingredients or shielding the stomach lining from irritating compounds. They are used to deliver pharmaceutical actives such as antacids, antibiotics and cardiovascular drugs as well as nutraceutical ingredients like probiotics, enzymes and certain vitamins. Buyers are pharmaceutical manufacturers, dietary-supplement and nutraceutical brands, and the contract encapsulation and fill-finish operations that produce softgels on their behalf.
The global enteric softgel capsules market stood at USD 2.75 billion in 2025. A forecast-period rate of 6.98% takes it to USD 4.99 billion by 2034, and the study reports every year in between, passing USD 2.02 billion in 2020, USD 2.6 billion in 2024, USD 2.91 billion in 2026 and USD 3.79 billion in 2030.
The type mix shifts over the period. Gelatin Type is the largest line in 2025 at USD 1.87 billion, a 68% share, moving to USD 2.89 billion and 57.9% by 2034. Vegetable Type grows fastest at 10.28%, taking its share from 32% to 42.1%, while Gelatin Type grows slowest at 5.04%. The lines gaining share are Vegetable Type. Gelatin Type lose share without losing revenue.
Cut by application, the largest line is Antacid and Antiflatulent Preparations: 34.2% of 2025 revenue, worth USD 0.94 billion, and 30.1% at USD 1.5 billion by 2034. Vitamins and Dietary Supplements grows faster at 9.55% against 5.33%, moving from 24% of revenue to 30.1% by 2034. Both this axis and the type one divide the same revenue, which is why they are alternative views rather than components.
Geographically, 34.2% of 2025 revenue sits in Asia Pacific (USD 0.94 billion rising to USD 1.9 billion) ahead of North America at 30.2% and USD 0.83 billion. Middle East and Africa is smallest, at 4.7%. Asia Pacific, Latin America and Middle East and Africa gain share across the period, so growth is not distributed evenly between regions.
The 2025 total is a triangulation of published figures and category proxies rather than a directly sourced total. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, two type lines and five segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 2.75 billion in 2025 to USD 4.99 billion in 2034, a compound annual rate of 6.98%, having reached USD 2.6 billion in 2024 from USD 2.02 billion in 2020.
- Gelatin Type is the largest type line at USD 1.87 billion in 2025, a 68% share, reaching USD 2.89 billion and 57.9% of revenue by 2034.
- At 10.28%, Vegetable Type grows faster than any other type line, moving from USD 0.88 billion and 32% of revenue in 2025 to USD 2.1 billion and 42.1% in 2034.
- The bull case puts 2034 revenue at USD 5.66 billion and the bear case at USD 4.44 billion, either side of the USD 4.99 billion base case, each with its own stated assumption in the full report.
- 34.2% of 2025 revenue is generated in Asia Pacific, worth USD 0.94 billion and rising to USD 1.9 billion by 2034; Middle East and Africa is smallest at 4.7%.
- 41.5% of Asia Pacific's base-year revenue comes from China alone: USD 0.39 billion in 2025, rising to USD 0.76 billion by 2034, which is why it is that region's worked example.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region rather than a single blended series.
Market Trends
Revenue Share, By by type
Base year 2025Gelatin Type leads with 68.0% of by type segment revenue.
Share of by type segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 6.98% compounding underneath both.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Vegetable Type outpaces Gelatin Type. Vegetable Type grows at 10.28% across 2026-2034 against 5.04% for Gelatin Type, the widest spread on the type axis. Vegetable Type takes its share of revenue from 32% to 42.1% while Gelatin Type gives up ground, from 68% to 57.9%. Revenue rises on both sides; USD 0.88 billion to USD 2.1 billion and USD 1.87 billion to USD 2.89 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Asia Pacific, Latin America and Middle East and Africa gain regional share. Asia Pacific moves from 34.2% of revenue in 2025 to 38.1% in 2034, worth USD 0.94 billion rising to USD 1.9 billion; Latin America moves from 6.9% of revenue in 2025 to 8% in 2034, worth USD 0.19 billion rising to USD 0.4 billion; Middle East and Africa moves from 4.7% of revenue in 2025 to 4.8% in 2034, worth USD 0.13 billion rising to USD 0.24 billion. The remaining regions grow in absolute terms while giving up share: North America at 30.2% moving to 27.1%, Europe at 24% moving to 22%. Growth is therefore not something a participant inherits from the market; it depends on which regions its revenue is weighted toward.
A continuation, not an inflection. Reading the series: USD 2.02 billion in 2020, USD 2.6 billion in 2024, USD 2.75 billion in 2025, USD 2.91 billion in 2026, USD 3.79 billion in 2030 and USD 4.99 billion in 2034. Against 6.37% through the historical period, the 6.98% forecast rate is a continuation; no year in the series interrupts it. For a participant that makes planning a question of capturing a share of steady expansion rather than timing a discontinuity, and it is why the type and regional mixes matter more to a forecast than the headline rate does.
Market Growth Factors
Vegetable Type carries the market's growth rate
Market Drivers
3- 01Vegetable Type carries the market's growth rate
The fastest line on the type axis is Vegetable Type, at 10.28% against the market's 6.98%, taking USD 0.88 billion to USD 2.1 billion and 32% of revenue to 42.1%. Because the spread to Gelatin Type at 5.04% is this wide, the headline 6.98% is a weighted result rather than a rate any single line achieves. A portfolio weighted away from it tracks below the market even in a market growing everywhere.
- 02Asia Pacific carries 34.2% of the base and keeps growing
The largest regional base is Asia Pacific: USD 0.94 billion in 2025 at 34.2% of the global total, USD 1.9 billion by 2034 and 38.1%. North America adds a further 30.2% at USD 0.83 billion, reaching USD 1.35 billion. Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.
- 03The base has grown every year since 2020
USD 2.02 billion in 2020, USD 2.6 billion in 2024 and USD 2.75 billion in 2025: 6.37% compound growth before the forecast period even begins. The forecast period then runs at 6.98%, ending 2034 at USD 4.99 billion. Because the growth is already in the record rather than in the projection, the rate is held flat across the forecast rather than ramped, and the risk in the number sits in the mix assumptions rather than in whether the market grows at all.
Growth drivers
| # | Growth driver | Impact | Gross contribution (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Growing use of enteric softgels in gut-targeted nutraceuticals | High | +0.95 | High | High | High |
| 2 | Expansion of contract encapsulation capacity in Asia Pacific | Medium-High | +0.55 | Medium | High | High |
| 3 | Rising volumes of chronic GI and cardiovascular drug formulations requiring acid-resistant delivery | Medium-High | +0.48 | Medium | Medium | Medium |
| 4 | Shift toward plant-based and vegetarian capsule shells | Medium | +0.3 | Low | Medium | Medium |
| 5 | Growth of direct-to-consumer e-commerce sales for supplement brands | Medium | +0.22 | Medium | Medium | High |
| 6 | Others | Low | +0.12 | Low | Low | Low |
| Total | +2.62 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Volatility in gelatin and specialty polymer raw material prices | Medium | −0.2 | Medium | Medium | Low |
| 2 | Regulatory complexity for enteric coating approval across regions | Medium | −0.12 | Medium | Medium | Medium |
| 3 | Competition from alternative delayed-release delivery formats | Low | −0.06 | Low | Low | Low |
| Total | −0.38 | |||||
Drivers contribute 2.62 Billion and restraints remove 0.38 Billion, a net 2.24 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 6.98% into its parts and three show up: an already-large base compounding, the type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
The study's downside path assumes slower supplement-brand adoption and continued raw-material cost pressure on gelatin and specialty polymers hold volumes below the base case, and ends 2034 at USD 4.44 billion against the USD 4.99 billion base case, the same USD 2.75 billion base year, a slower forecast period.
- 02The largest line is not the fastest
Gelatin Type carries 68% of 2025 revenue at USD 1.87 billion but compounds at 5.04% against 6.98% for the market, taking its share to 57.9% by 2034 even as revenue rises to USD 2.89 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
A bull case of USD 5.66 billion by 2034, against USD 4.99 billion in the base case, turns on a single stated assumption: faster adoption of enteric softgel formats by dietary-supplement brands and quicker capacity additions at contract encapsulation facilities in Asia Pacific lift volumes above the base case. The USD 2.75 billion 2025 base is common to both.
- 02Vegetable Type is where share changes hands
Share on the type axis moves toward Vegetable Type, from 32% in 2025 to 42.1% in 2034, on 10.28% growth against the market's 6.98% and revenue rising from USD 0.88 billion to USD 2.1 billion. Taking position there does not require displacing whoever holds Gelatin Type, which is the harder and more expensive fight.
Market Challenges
Revenue is concentrated in Gelatin Type
Market Challenges
2- 01Revenue is concentrated in Gelatin Type
USD 1.87 billion of 2025 revenue sits in Gelatin Type, 68% of the total, and it is still 57.9% at USD 2.89 billion nine years later. No other single change on the type axis moves the total as much as a change in demand for that one line.
- 02One country drives the leading region
Of Asia Pacific's USD 0.94 billion in 2025, USD 0.39 billion (41.5%) comes from China alone, rising to USD 0.76 billion by 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
5 axesThe market is divided by type and by application, end user, distribution channel and manufacturing technology; five axes in all. Revenue does not add across them: each is a different cut of the same total.
There are two lines on the type axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: one gains it, the other gives it up.
By Type · 2 segments
Gelatin Type Held the Dominant Share of the Type Segment in 2025
- Largest Gelatin Type · 68%
- Fastest Vegetable Type · 10.3%
- Moves most Gelatin Type · -10.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Gelatin Type | $1.87B | 68% | $2.89B | 57.9%-10.1 | 5% |
| Vegetable Type | $0.88B | 32% | $2.10B | 42.1%+10.1 | 10.3% |
Gelatin capsules lead because established encapsulation lines, well-understood shell chemistry and lower per-unit material cost keep them the default choice for contract manufacturers filling antacid and antibiotic formulations. Vegetable-based shells are growing fastest as brand owners respond to non-animal and religious-dietary sourcing preferences, and as newer plant-polymer shell formulations close the moisture-barrier gap that once limited their use in enteric coatings. The order does not change: Gelatin Type is still largest in 2034, and what moves is how much it holds. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Application · 5 segments
Antacid and Antiflatulent Preparations Led by Application in 2025, with Vitamins and Dietary Supplements Growing Fastest
- Largest Antacid and Antiflatulent Preparations · 34.2%
- Fastest Vitamins and Dietary Supplements · 9.6%
- Moves most Vitamins and Dietary Supplements · +6.1 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Antacid and Antiflatulent Preparations | $0.94B | 34.2% | $1.50B | 30.1%-4.1 | 5.3% |
| Antibiotic and Antibacterial Drugs | $0.61B | 22.2% | $0.90B | 18%-4.2 | 4.4% |
| Vitamins and Dietary Supplements | $0.66B | 24% | $1.50B | 30.1%+6.1 | 9.6% |
| Cold, Cough and Analgesic Preparations | $0.33B | 12% | $0.65B | 13%+1 | 7.8% |
| Others | $0.21B | 7.6% | $0.44B | 8.8%+1.2 | 8.6% |
Antacid and antiflatulent preparations lead because enteric coatings are essential for delivering acid-sensitive actives past the stomach lining, and this remains the largest chronic-use category. Vitamins and dietary supplements are growing fastest as consumers shift toward preventive and gut-targeted nutrition, pushing supplement brands to adopt enteric softgel formats once reserved mainly for prescription drugs. The order does not change: Antacid and Antiflatulent Preparations is still largest in 2034, and what moves is how much it holds.
By End User · 3 segments
Scale in Pharmaceutical Manufacturers and Growth in Nutraceutical and Dietary Supplement Companies Define the End user Axis
- Largest Pharmaceutical Manufacturers · 46.2%
- Fastest Nutraceutical and Dietary Supplement Companies · 8.5%
- Moves most Pharmaceutical Manufacturers · -6.1 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical Manufacturers | $1.27B | 46.2% | $2B | 40.1%-6.1 | 5.2% |
| Nutraceutical and Dietary Supplement Companies | $1.10B | 40% | $2.30B | 46.1%+6.1 | 8.5% |
| Contract Manufacturing Organizations | $0.38B | 13.8% | $0.69B | 13.8% | 6.9% |
Pharmaceutical manufacturers lead because prescription and OTC drug formulators have used enteric softgels longest and hold the regulatory filings that keep switching costs high. Nutraceutical and dietary supplement companies are growing fastest as omega-3, probiotic and gut-health brands adopt enteric shells to protect actives through the stomach, a use case that barely existed for this format a decade ago. Leadership changes hands: Nutraceutical and Dietary Supplement Companies is the largest line by 2034, not Pharmaceutical Manufacturers.
By Distribution Channel · 3 segments
Online Retail Outpaces the Axis While Direct/Institutional Sales Holds the Largest Share
- Largest Direct/Institutional Sales · 58.2%
- Fastest Online Retail · 13.5%
- Moves most Online Retail · +8.4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Direct/Institutional Sales | $1.60B | 58.2% | $2.59B | 51.9%-6.3 | 5.5% |
| Retail Pharmacies and Drug Stores | $0.83B | 30.2% | $1.40B | 28.1%-2.1 | 6% |
| Online Retail | $0.32B | 11.6% | $1B | 20%+8.4 | 13.5% |
Direct and institutional sales lead because large pharmaceutical and nutraceutical manufacturers buy encapsulation volumes under multi-year supply agreements rather than through intermediaries. Online retail is growing fastest as finished-dose supplement brands increasingly sell direct to consumers, pulling private-label softgel demand toward e-commerce fulfillment models that barely existed for this category before recent years. Direct/Institutional Sales remains the largest line through 2034, so the axis changes in proportion rather than in order.
By Manufacturing Technology · 2 segments
Scale in Rotary Die Encapsulation and Growth in Seamless Encapsulation Define the Manufacturing technology Axis
- Largest Rotary Die Encapsulation · 81.8%
- Fastest Seamless Encapsulation · 10.2%
- Moves most Rotary Die Encapsulation · -5.8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Rotary Die Encapsulation | $2.25B | 81.8% | $3.79B | 76%-5.8 | 6% |
| Seamless Encapsulation | $0.50B | 18.2% | $1.20B | 24%+5.8 | 10.2% |
Rotary die encapsulation leads because it remains the industry-standard process for high-volume softgel production, with the equipment base and operator expertise already in place at most contract fillers. Seamless encapsulation is growing fastest as it produces a more uniform enteric coating with fewer seam-related failure points, a quality advantage that matters more as more prescription-strength actives move into this format. Rotary Die Encapsulation remains the largest line through 2034, so the axis changes in proportion rather than in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The 2nd-largest region covered — 3.1 points of share move elsewhere by 2034, while revenue still grows 1.6×.
- Rank 2 of 5
- 2025 share 30.2%
- By 2034 27.1%
- Revenue $0.83B → $1.35B
North America holds 30.2% of the global enteric softgel capsules market in 2025, worth USD 0.83 billion on the way to USD 1.35 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.
By 2034 the share stands at 27.1%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.
The type mix reported at global level applies here, with Gelatin Type the largest line at 68% of 2025 revenue and Vegetable Type the fastest-growing at 10.28%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 81.9% of it, growing 1.6×.
- In region 1 of 2
- Of region 81.9%
- Of global 24.7%
- Revenue $0.68B → $1.08B
81.9% of North America's base-year revenue comes from the United States; USD 0.68 billion, rising to USD 1.08 billion by 2034. Because it is 81.9% of the region in the base year, North America's totals move with this one country rather than with a spread of them. The region itself runs USD 0.83 billion to USD 1.35 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Gelatin Type at 68% of 2025 revenue, easing to 57.9% by 2034, and the fastest is Vegetable Type at 10.28%, from 32% to 42.1%. Its 81.9% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.
In the United States, enteric-coated softgel capsules fall under the oversight of the Food and Drug Administration, with the applicable pathway depending on whether the product is marketed as a conventional pharmaceutical or as a dietary supplement. Pharmaceutical-grade softgels require approval through the New Drug Application or Abbreviated New Drug Application process, demonstrating safety, efficacy, and manufacturing quality under current Good Manufacturing Practice rules. Supplement-grade products instead fall under the Dietary Supplement Health and Education Act, which does not require premarket approval but obligates manufacturers to follow dietary supplement current Good Manufacturing Practice regulations, substantiate label claims, and avoid disease-treatment claims reserved for drugs. Labelling must accurately disclose ingredients, dosage form, and supplement facts.
The suppliers tracked in this study (Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd.) compete in the United States across the type lines above. Gelatin Type, at 68% of 2025 revenue, is where the volume sits, and Vegetable Type, growing at 10.28%, is where position changes hands over the forecast period. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 1.8×.
- In region 2 of 2
- Of region 18.1%
- Of global 5.5%
- Revenue $0.15B → $0.27B
Within North America, Canada accounts for 18.1% of regional revenue and 5.5% of the global total, worth USD 0.15 billion in 2025 and USD 0.27 billion by 2034.
Europe Market Analysis
The 3rd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 3 of 5
- 2025 share 24%
- By 2034 22%
- Revenue $0.66B → $1.10B
24% of the global enteric softgel capsules market sits in Europe in 2025, worth USD 0.66 billion rising to USD 1.1 billion in 2034. Among the five regions it ranks third by revenue in both years.
Its share moves to 22% by 2034, a shift in share rather than in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Within the region the type split tracks the global one; 68% of 2025 revenue in Gelatin Type, fastest growth of 10.28% in Vegetable Type. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.6×.
- In region 1 of 2
- Of region 36.4%
- Of global 8.7%
- Revenue $0.24B → $0.39B
36.4% of Europe's base-year revenue comes from Germany; USD 0.24 billion, rising to USD 0.39 billion by 2034. It accounts for 36.4% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 0.66 billion in 2025 and USD 1.1 billion in 2034, it is the country the full report breaks out in detail.
Germany buys along the same lines as the market globally; Gelatin Type first at 68% of 2025 revenue and 57.9% in 2034, Vegetable Type fastest at 10.28% on a share moving from 32% to 42.1%. Since 36.4% of Europe's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Germany by type separately.
In Germany, enteric softgel capsules are regulated within the broader European Union medicinal products and food supplement frameworks, with the German Federal Institute for Drugs and Medical Devices, BfArM, overseeing products classified as medicinal. A softgel marketed as a medicinal product requires authorization either nationally or through the European Medicines Agency's centralized procedure, with conformity to Good Manufacturing Practice and the EU Pharmaceutical Directive's quality and labelling standards. Where the softgel is classified instead as a food supplement, it falls under the EU Food Supplements Directive, requiring notification to national authorities, compliance with maximum permitted ingredient levels, and labelling that avoids medicinal claims while disclosing composition, allergens, and recommended use clearly.
Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd. are the suppliers covered in Germany. The commercially relevant division is 68% of 2025 revenue in Gelatin Type, where the volume is, against 10.28% growth in Vegetable Type, where share moves.
France
2nd-largest in Europe, growing 1.6×.
- In region 2 of 2
- Of region 24.2%
- Of global 5.8%
- Revenue $0.16B → $0.25B
France is sized at USD 0.16 billion in 2025, rising to USD 0.25 billion by 2034; 5.8% of global revenue and 24.2% of Europe. It is reported separately from Germany across every segmentation axis in the full report.
Asia Pacific Market Analysis
The largest region covered, and the one gaining the most — it picks up 3.9 points of share by 2034, while revenue still grows 2.0×.
- Rank 1 of 5
- 2025 share 34.2%
- By 2034 38.1%
- Revenue $0.94B → $1.90B
In Asia Pacific, 34.2% of global revenue puts 2025 at USD 0.94 billion rising to USD 1.9 billion in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
Its share rises to 38.1% over the forecast period, so the region grows faster than the market's 6.98% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Within the region the type split tracks the global one; 68% of 2025 revenue in Gelatin Type, fastest growth of 10.28% in Vegetable Type. Per-axis and per-country detail for Asia Pacific sits in the full report.
China
The largest market in Asia Pacific, growing 1.9×.
- In region 1 of 3
- Of region 41.5%
- Of global 14.2%
- Revenue $0.39B → $0.76B
China is the largest market within Asia Pacific, generating USD 0.39 billion in 2025 and projected to reach USD 0.76 billion by 2034. 41.5% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.94 billion in 2025 and USD 1.9 billion in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Gelatin Type at 68% of 2025 revenue, easing to 57.9% by 2034, and the fastest is Vegetable Type at 10.28%, from 32% to 42.1%. With 41.5% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports China by type separately.
In China, enteric softgel capsules are regulated according to their classification as either a pharmaceutical or a health food product. Pharmaceutical-grade softgels fall under the National Medical Products Administration, which requires drug registration, clinical evidence, and conformity with Good Manufacturing Practice before market entry. Health food, or so-called Blue Hat, softgels are instead regulated by the State Administration for Market Regulation, requiring registration or filing depending on ingredient novelty, along with adherence to national food safety standards and labelling rules that prohibit therapeutic claims. Both routes demand accurate disclosure of ingredients, dosage instructions, and manufacturer information, alongside facility licensing appropriate to the product's classification.
Competition in China runs between the suppliers this study tracks: Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd.. Gelatin Type, at 68% of 2025 revenue, is where the volume sits, and Vegetable Type, growing at 10.28%, is where position changes hands over the forecast period.
India
2nd-largest in Asia Pacific, growing 2.2×.
- In region 2 of 3
- Of region 22.3%
- Of global 7.6%
- Revenue $0.21B → $0.46B
Within Asia Pacific, India accounts for 22.3% of regional revenue and 7.6% of the global total, worth USD 0.21 billion in 2025 and USD 0.46 billion by 2034.
Japan
3rd-largest in Asia Pacific, growing 1.9×.
- In region 3 of 3
- Of region 16%
- Of global 5.5%
- Revenue $0.15B → $0.29B
Within Asia Pacific, Japan accounts for 16% of regional revenue and 5.5% of the global total, worth USD 0.15 billion in 2025 and USD 0.29 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered — it picks up 1.1 points of share by 2034, while revenue still grows 2.1×.
- Rank 4 of 5
- 2025 share 6.9%
- By 2034 8%
- Revenue $0.19B → $0.40B
USD 0.19 billion of 2025 revenue is generated in Latin America, 6.9% of the global enteric softgel capsules market and reaches USD 0.4 billion by 2034. Among the five regions it ranks fourth by revenue in both years.
Its share rises to 8% over the forecast period, so the region grows faster than the market's 6.98% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
Within the region the type split tracks the global one; 68% of 2025 revenue in Gelatin Type, fastest growth of 10.28% in Vegetable Type. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 1.9×.
- In region 1 of 2
- Of region 52.6%
- Of global 3.6%
- Revenue $0.10B → $0.19B
52.6% of Latin America's base-year revenue comes from Brazil; USD 0.1 billion, rising to USD 0.19 billion by 2034. At 52.6% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Against regional totals of USD 0.19 billion in 2025 and USD 0.4 billion in 2034, it is the country the full report breaks out in detail.
The type pattern in Brazil is the global one: 68% of 2025 revenue in Gelatin Type, 57.9% by 2034, against 10.28% growth in Vegetable Type taking it from 32% to 42.1%. Since 52.6% of Latin America's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Revenue by type for Brazil is reported separately in the full report.
In Brazil, enteric softgel capsules are regulated by the National Health Surveillance Agency, ANVISA, which classifies the product according to its intended use as either a medicine or a food supplement. Medicinal softgels require registration demonstrating safety, quality, and efficacy, along with adherence to Good Manufacturing Practice standards enforced through ANVISA inspection. Softgels marketed as food supplements fall under ANVISA's specific food supplement resolution, which sets requirements for permitted ingredients, maximum intake recommendations, and labelling that must avoid disease-related claims while clearly stating composition and directions for use. Import and domestic manufacture alike require sanitary licensing and ongoing compliance with ANVISA's post-market surveillance obligations.
The suppliers tracked in this study (Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd.) compete in Brazil across the type lines above. Volume sits in Gelatin Type at 68% of 2025 revenue; movement sits in Vegetable Type at 10.28% growth.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 31.6%
- Of global 2.2%
- Revenue $0.06B → $0.12B
Within Latin America, Mexico accounts for 31.6% of regional revenue and 2.2% of the global total, worth USD 0.06 billion in 2025 and USD 0.12 billion by 2034.
Middle East and Africa Market Analysis
The 5th-largest region covered — it picks up 0.1 points of share by 2034, while revenue still grows 1.8×.
- Rank 5 of 5
- 2025 share 4.7%
- By 2034 4.8%
- Revenue $0.13B → $0.24B
USD 0.13 billion of 2025 revenue is generated in Middle East and Africa, 4.7% of the global enteric softgel capsules market and reaches USD 0.24 billion by 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
By 2034 the share has moved up to 4.8%, on growth above the market's own 6.98%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Gelatin Type leads here as it does globally, at 68% of 2025 revenue, and Vegetable Type again grows fastest at 10.28%. Middle East and Africa is reported axis by axis and country by country in the full study.
Saudi Arabia
The largest market in Middle East and Africa, growing 1.6×.
- In region 1 of 2
- Of region 38.5%
- Of global 1.8%
- Revenue $0.05B → $0.08B
USD 0.05 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 0.08 billion by 2034. At 38.5% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 0.13 billion in 2025 and USD 0.24 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Saudi Arabia buys along the same lines as the market globally; Gelatin Type first at 68% of 2025 revenue and 57.9% in 2034, Vegetable Type fastest at 10.28% on a share moving from 32% to 42.1%. Since 38.5% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. The full report reports Saudi Arabia by type separately.
In Saudi Arabia, enteric softgel capsules fall under the jurisdiction of the Saudi Food and Drug Authority, SFDA, which determines classification as either a pharmaceutical or a food supplement depending on ingredient composition and intended claims. Pharmaceutical-grade softgels require registration demonstrating safety and quality in line with SFDA's drug regulations and Good Manufacturing Practice conformity. Food supplement softgels instead follow the SFDA's food supplement regulation, requiring product notification or registration, ingredient limits aligned with Gulf Cooperation Council standards, and labelling in Arabic disclosing composition, usage directions, and cautionary statements. Importers and manufacturers must hold valid SFDA licensing and maintain conformity throughout the product's distribution.
Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd. are the suppliers covered in Saudi Arabia. Two different problems sit on the same axis: holding Gelatin Type at 68% of 2025 revenue, and taking Vegetable Type while it grows at 10.28%.
South Africa
2nd-largest in Middle East and Africa, growing 2.0×.
- In region 2 of 2
- Of region 23.1%
- Of global 1.1%
- Revenue $0.03B → $0.06B
Within Middle East and Africa, South Africa accounts for 23.1% of regional revenue and 1.1% of the global total, worth USD 0.03 billion in 2025 and USD 0.06 billion by 2034.
Request this sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, end user, distribution channel, manufacturing technology, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Gelatin Type Volume and Vegetable Type Momentum
Suppliers in scope: Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules and Qualicaps Co., Ltd..
Where suppliers actually compete is along the type axis. Gelatin Type is 68% of 2025 revenue at USD 1.87 billion and still 57.9% in 2034, so it is where the volume sits and where an incumbent's position is hardest to move. Vegetable Type, compounding at 10.28% against 5.04% for Gelatin Type, is where share changes hands over the forecast period. A supplier positioned in one is not automatically positioned in the other, which is what keeps a field of this size viable in a market of USD 2.75 billion.
Suppliers in this market compete mainly on encapsulation scale and formulation know-how rather than on price alone. Larger players hold an edge in regulatory and approval experience, since enteric coating formulations for pharmaceutical actives require documentation that smaller fillers often cannot support, and in supply reliability for multi-year contract manufacturing agreements. Mid-size and regional suppliers compete on flexibility, faster changeover for smaller nutraceutical brand orders, and private-label capability for supplement companies that do not want to build in-house filling capacity. Distribution and channel reach matters most for suppliers serving retail and online supplement brands directly.
The regional picture sets the entry cost: 34.2% of revenue is in Asia Pacific and 30.2% in North America, so a credible global position requires both, while Middle East and Africa at 4.7% can be served opportunistically.
Per-company profiles, financials, share and development history are in the full report and not here.
List of Key Enteric Softgel Capsules Market Companies Profiled
14 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Aenova Group GmbH(Germany)
- BASF SE(Germany)
- Catalent Inc.(United States)
- Colorcon Inc.(United States)
- Fuji Capsule Co.Ltd.(Japan)
- Lonza Group AG(Switzerland)
- Now Health Group Inc.(United States)
- ProCaps Group(Colombia)
- Super Spectrim(India)
- Thermo Fisher Scientific Inc.(United States)
- Captek Softgel International(United States)
- Sirio Pharma Co., Ltd.(China)
- ACG Capsules(India)
- Qualicaps Co., Ltd.(Japan)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 5 axes (Type, Application, End User, Distribution Channel, Manufacturing Technology), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 14 key companies, and the research methodology behind every estimate.
Segmentation
5 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Enteric Softgel Capsules Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Enteric Softgel Capsules Market Overview, By Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Enteric Softgel Capsules Market Overview, By Application, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Enteric Softgel Capsules Market Overview, By End User, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Enteric Softgel Capsules Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Enteric Softgel Capsules Market Overview, By Manufacturing Technology, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Enteric Softgel Capsules Market Size — Segment Comparison
Chapter 22.Global Enteric Softgel Capsules Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 23.North America Enteric Softgel Capsules Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 24.Europe Enteric Softgel Capsules Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 25.Asia Pacific Enteric Softgel Capsules Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 26.Latin America Enteric Softgel Capsules Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 27.Middle East and Africa Enteric Softgel Capsules Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 28.Application / Use-Case Analysis
Chapter 29.Vendor Capability Scorecard
Chapter 30.Scenario Forecasts
Chapter 31.Top 10 Key Clients of Top 10 Players
Chapter 32.Top 10 Suppliers
Chapter 33.Competitive Landscape
Chapter 34.Partnerships & M&A
Chapter 35.Key Vendor Analysis
Chapter 36.Marketing Strategy Analysis, Distributors & Traders
Chapter 37.Outlook of the Market
Chapter 38.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
5 axesBy Type
2- 01Gelatin Type
- 02Vegetable Type
By Application
5- 01Antacid and Antiflatulent Preparations
- 02Antibiotic and Antibacterial Drugs
- 03Vitamins and Dietary Supplements
- 04Cold, Cough and Analgesic Preparations
- 05Others
By End User
3- 01Pharmaceutical Manufacturers
- 02Nutraceutical and Dietary Supplement Companies
- 03Contract Manufacturing Organizations
By Distribution Channel
3- 01Direct/Institutional Sales
- 02Retail Pharmacies and Drug Stores
- 03Online Retail
By Manufacturing Technology
2- 01Rotary Die Encapsulation
- 02Seamless Encapsulation
Segment categories shown for scope reference. See the Summary tab for revenue share by By Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary interviews were conducted with procurement and formulation leads at pharmaceutical and dietary-supplement manufacturers, production and quality managers at contract encapsulation facilities, and regulatory affairs staff responsible for enteric-coating approvals. Distribution and channel contacts at pharmacy wholesalers and e-commerce supplement brands were included to validate channel-level assumptions. Sampling weighted North America, Europe and Asia Pacific most heavily, reflecting where encapsulation capacity and end-product formulation are concentrated, with a smaller number of conversations in Latin America and the Middle East to confirm regional demand patterns and import dependence. Findings were cross-checked against public regulatory filings and company disclosures where available before being folded into the estimation model.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Enteric Softgel Capsules Market projected to reach?
USD 4.99 Billion by 2034, CAGR 6.98%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
Asia Pacific leads with 34.2% of global revenue through 2034.
05Which segment leads the market?
Gelatin Type is the largest line by type, at 68% of revenue in 2025.
06Who are the key companies profiled?
Aenova Group GmbH, BASF SE, Catalent Inc., Colorcon Inc., Fuji Capsule Co.Ltd., Lonza Group AG, Now Health Group Inc., ProCaps Group, Super Spectrim, Thermo Fisher Scientific Inc., Captek Softgel International, Sirio Pharma Co., Ltd., ACG Capsules, Qualicaps Co., Ltd.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.